Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

Following its recently announced partnership with Novo Nordisk, OpenAI is introducing a new reasoning model, GPT-Rosalind, to ...

Abbott is dealing with integrating a big new buyout into its business alongside a weaker-than-expected respiratory disease ...

China’s biotech rise has been a persistent concern for federal health leaders, Congress, and many biopharma executives. | ...

Kailera Therapeutics appears to have set a new benchmark for biotech IPOs with an upsized $625 million offering to fund its ...

The traditional gold standard of clinical trials with a randomized, placebo-controlled design involving hundreds of patients ...

Clinical site selection platform RyghtAI has launched a search engine designed to give drug developers and contract research ...

Aligos Therapeutics has secured a $25 million cash infusion in return for selling the China rights to its phase 2-stage ...

Storm Therapeutics has closed a $56 million series C financing as the British biotech kicks off a phase 2 sarcoma trial of ...

After its bet on a rare eye disease gene therapy ended in a phase 3 fail last year, Johnson & Johnson is now returning the ...

To Ocugen CEO Shankar Musunuri, Ph.D., most gene therapy biotechs today lack vision. | Many gene therapy outfits focus on ...

A slow start to 2026 has put first-time biotech financings on course for their worst year since before the pandemic, reducing ...